contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-0912-2025-gubra-og-impero-compliance-simplified

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Sales

Jesper Thomsen

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.

Gubra

Impero is a Danish Software-as-a-Service (SaaS) company that provides a compliance management platform. The Impero platform enables companies to easily manage compliance through the automation of risk and control management, documentation, and reporting. Impero empowers companies to become more compliant in a scalable, digital, intuitive, and – most importantly – easy way. Impero is listed at Nasdaq First North in Denmark.

Impero

Dagens aktienyheder med Gubra og Impero - Compliance. Simplified.

Dagens aktienyheder 09/12-2025: <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/#" data-entity-urn="urn:li:fsd_company:1434445" data-guid="13" data-object-urn="urn:li:organization:1434445" data-original-text="Gubra" data-test-ql-mention="true">Gubra og</a> <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/#" data-entity-urn="urn:li:fsd_company:5103490" data-guid="12" data-object-urn="urn:li:organization:5103490" data-original-text="Impero - Compliance. Simplified." data-test-ql-mention="true">Impero - Compliance. Simplified.</a>
I g&#xe5;r annoncerede Gubra, at deres partner Boehringer Ingelheim har avanceret sin first-in-class triple-agonist-peptid, BI 303470, til midt-fase klinisk udvikling efter lovende fase I-data med god sikkerhed og tidlige v&#xe6;gttabssignaler. Programmet indeb&#xe6;rer milep&#xe6;lsbetalinger p&#xe5; op til DKK 1,8 mia. samt royalties i det lave enkeltcifrede til lave tocifrede interval, og Boehringer Ingelheims fremdrift udg&#xf8;r en vigtig validering af b&#xe5;de stoffet og Gubras streaMline-platform. AbbVie&#x2019;s ABBV-295 og Gubras egen UCN2-kandidat forbliver dog de st&#xf8;rste v&#xe6;rdidrivere i vores model. L&#xe6;s hele kommentaren her: <a href="https://www.inderes.dk/analyst-comments/gubra-partner-progresses-obestiy-asset-into-mid-stage-further-validating-differentiated-obesity-approach" target="_blank" rel="noopener">https://www.inderes.dk/analyst-comments/gubra-partner-progresses-obestiy-asset-into-mid-stage-further-validating-differentiated-obesity-approach</a>
Impero kan her til morgen annoncere, at de her besluttet at rejse DKK 15 mio. igennem udstedelse og privat placering af 2.343.750 nye aktier i en direkte placering, hvor de allerede har modtaget tegningsforpligtelser for alle nye aktier fra en begr&#xe6;nset kreds af professionelle investorer, herunder udvalgte eksisterende aktion&#xe6;rer samt medlemmer af ledelsen og bestyrelsen. Transaktionen forventes gennemf&#xf8;rt den 16. december 2025. kapitalforh&#xf8;jelsen giver et et bruttoprovenu p&#xe5; DKK 15 mio. De nye aktier udstedes til DKK 6,40 pr. aktie, svarende til lukkekursen den 8. december 2025. &#xc5;rsagen til kapitalforh&#xf8;jelsen er &#xf8;ge den finansielle fleksibilitet og &#xf8;ge muligheden for at investere i kommercielle muligheder. Dette er i tr&#xe5;d med selskabet meldinger om, at de kunne blive selvfinansierende i l&#xf8;bet af 2026, men ogs&#xe5; unders&#xf8;gelse om det gav mere v&#xe6;rdi for aktion&#xe6;rer at &#xf8;ge investeringer i v&#xe6;kst ved at hente kapital. Med en bruttomargin p&#xe5; +95% og en meget lav churn, er der en h&#xf8;j langsigtet v&#xe6;rdiskabelse i at hente nye kunder ind s&#xe5; l&#xe6;nge det kan ske balanceret (ikke for h&#xf8;j cash flow/til ny ARR ratio). L&#xe6;s hele nyheden her: <a href="https://www.inderes.dk/releases/impero-strengthens-its-capital-position-by-raising-dkk-15m-in-a-private-placement" target="_blank" rel="noopener">https://www.inderes.dk/releases/impero-strengthens-its-capital-position-by-raising-dkk-15m-in-a-private-placement</a>
Disclaimer: HC Andersen Capital modtager betaling fra de n&#xe6;vnte selskaber for en digital IR abonnementsaftale. /Jesper Thomsen d. 09/12-2025 kl. 09:00.

Dagens aktienyheder 09/12-2025: Gubra og Impero - Compliance. Simplified.

Stay up to date